Ophthalmic Drugs Market Will Reach $9.7bn By 2024: Latest Report By Radiant Insights, Inc

Ophthalmic Drugs Market all set to increase dramatically across the forecast period of 2014-2024

Which ophthalmic drugs lead the market in 2013? Will the same drugs be as successful in 2018? How will this landscape change across the next 10 years? Which trial drugs are likely to make an impact? Only one report will tell you the answers. Simply by ordering and reading GMR Data’s new ‘Ophthalmic Drugs; Data, Analysis and Forecasts to 2024’ report, you can stay ahead of your competition. It really is that simple.

Browse Full Research Report With TOC On “Ophthalmic Drugs; Data, Analysis and Forecasts to 2024” at: http://www.radiantinsights.com/research/ophthalmic-drugs-data-analysis-and-forecasts-to-2024

The global ophthalmic drugs market will reach $9.7bn by 2024. The US market growth will be slow compared to other markets predominantly due to major drug patent expiry and generic erosion. For example:

• Xalabrands from Pfizer used for treatment of Glaucoma expired in the US in March 2011.

• Azopt by Alcon used for treatment of Glaucoma expired in the US in October 2012.

• Lumigan by Allergan used for treatment of Glaucoma expired in the US in 2013.

• Restasis from Allergan used for treatment of Dry eye will expire in the US in May 2014.

• Travatan by Alcon used for treatment of Glaucoma will expire in the US in 2014.

• Combigan by Allergan used for treatment of Glaucoma will expire in the US in 2022.

• Lucentis from Novartis used for treatment of Retinal Disorder will expire in the US in June 2020.

Restasis by Allergan is the market-leading drug in the ophthalmic market with sales of $1bn across 2013. Will it be able to see off the competition for the next 5 years? The next 10 years? This report tells you. Which other countries contribute most? This report tells you in a concise, focused and easily accessible format.

Browse All Reports of This Category at: http://www.radiantinsights.com/catalog/pharmaceutical

But how will these country’s markets develop? This report will tell you – TODAY.

Global incidences of AMD, Glaucoma and Diabetic Retinopathy are all set to increase dramatically across the forecast period of 2014-2024; this will have the knock-on effect of driving sales of key drugs for treatment i.e. Lucentis and Eylea, as well as driving R&D. How much is being spent on R&D – and which drugs are likely to see a return? And how quickly?

Which new drugs will we see in the ophthalmic market across 2014-2024?

In December 2013 Santen announced that Ikervis (Ciclosporin / Cyclokat) was filed to the EMA, in doing so the EMA will begin its regulatory process. Diquas, which was launched in 2010 by Santen Pharma in Japan, China and other Asian markets, and despite US trials being unsuccessful, is expected to gain approval in the EU early in our forecast period.

Other key ophthalmic drugs currently under taking trials include:

• Sirolimus (By Santen, in Phase III US)

• Tafluprost/Timolol maleate (By Santen, filed for NDA)

• Catioprost (By Santen in Phase 2)

PLUS – In-depth country analysis – Discover which countries and regions will drive the ophthalmic drugs market to 2024?

As well as primary and secondary research sources, we have interviewed leading ophthalmic specialists within big pharma, R&D, wholesalers, distributors, marketeers and key clinical organisations. From these interviews we have selected original, exclusive, transcribed interviews with leading specialists in their field – This information is not available anywhere else.

This report is the single tool to equip you with the latest trends in all regional markets and why all stakeholders demand development of Ophthalmic Drugs. This report will arm you with all you and your company require to develop, price, launch and market an ophthalmic drug.

Get Sample Report Copy @ www.radiantinsights.com/research/ophthalmic-drugs-data-analysis-and-forecasts-to-2024#tabs-4

With over 150 pages, and over 140 charts, tables and graphs, this dedicated specialist report will ensure you remain equipped and fully informed, to succeed in this competitive market.

 Explore Other Reports By Radiant Insights, Inc at

• Lymphoma Treatment Drugs Companies in China:
  http://www.radiantinsights.com/research/lymphoma-treatment-drugs-companies-in-china

• Central Nervous System Disorder Drugs Companies in China:
  http://www.radiantinsights.com/research/central-nervous-system-disorder-drugs-companies-in-china

About Radiant Insights

Radiant Insights is a market research and consulting company offering syndicated research studies, customized reports, and consulting services. Our market research studies are designed to facilitate strategic decision making, on the basis of extensive and in-depth quantitative information, supported by extensive analysis and industry insights. Using a patented and robust research methodology, we publish exhaustive research reports covering a host of industries such as Technology, Chemicals, Materials, and Energy. Radiant Insights has a strong base of analysts, consultants and domain experts, with global experience helping us deliver excellence in all research projects we undertake. 

Logo: http://www.abnewswire.com/pressreleases/wp-content/uploads/2016/03/1458283158.png

“Radiant Insights”

Media Contact
Company Name: Radiant Insights, Inc.
Contact Person: Michelle Thoras, Corporate Sales Specialist – USA
Email: sales@radiantinsights.com
Phone: (415) 349-0054, Toll Free: 1-888-202-9519
Address:28 2nd Street, Suite 3036
City: San Francisco
State: California
Country: United States
Website: http://www.radiantinsights.com/research/ophthalmic-drugs-data-analysis-and-forecasts-to-2024

Source: ABNewswire

ReleaseID: 56638